Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

Not Applicable

Completed

• Conditions: Systemic Sclerosis; Primary Raynaud Disease

• Registration Number: NCT02212249
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-04-23
• Study Start: 2014-05
• Study First Submitted QC: 2014-08-06
• Study First Posted: 2014-08-08
• Status Verified: 2016-03
• Primary Completion: 2016-03
• Study Completion: 2016-03
• Last Update Submitted: 2016-03-23
• Last Update Posted: 2016-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

• group 1: systemic sclerosis
• group 2: raynaud primary disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Level of soluble Ve-cadherin and antibody VE-cadherin with ELISA TEST in Scleroderma group versus Primary Raynaud's Phenomenon	At 30 days average	Level of human sVE and antibody VE-cadherin in blood will be determined by ELISA test in both groups Scleroderma and Primary Raynaud's Phenomenon.; The methodology of dosage of sVE is based on the pattern:WO/2008/062314 The methodolody of the dosage of antibody VE-cadherin is based on the pattern WO/2012/136820 .; Group Scleroderma (N=60) versus Primary Raynaud's Phenomenon (N=20). Shapiro test.

Trial Locations

Locations (1)

Grenoble University Hospital; 🇫🇷 Grenoble, France